TICKERNERD
Menu
IMNNIMNNHealthcare · Biotechnology

IMNN Stock Forecast: Imunon, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$1.47
−0.34% on the day

The 4 Wall Street analysts covering Imunon, Inc. hold a median 12-month price target of $13 — +787.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.2M
Ticker Nerd rank
23 / 100
Median analyst target
$13
Analysts covering
4
Revenue$0.0
Operating income−$4.3M
Net income−$4.2M
Free cash flow−$4.0M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.3%
1M
−11.2%
YTD
−61.5%
1Y
−74.5%
From 52W high
−73.7%
From 52W low
+1.0%
$1.45
$5.58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMNN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Imunon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Volatility
85
Revisions
71
Growth
45
Accruals
25
Value
21
Quality
17
Issuance
4
Momentum
3

Size (93): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMNN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMNN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26IMNNHigh $25Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $10Median $13High $25

The green dot is the last close — the median target sits +787.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Apr 2026Maxim GroupInitiatesBuy$10
19 May 2025D. Boral CapitalDowngradeHold—
13 May 2025D. Boral CapitalMaintainsBuy—
7 May 2025D. Boral CapitalMaintainsBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
24 Mar 2025D. Boral CapitalMaintainsBuy—
27 Feb 2025D. Boral CapitalMaintainsBuy—
19 Feb 2025D. Boral CapitalMaintainsBuy—
24 Jan 2025D. Boral CapitalMaintainsBuy—
19 Dec 2024D. Boral CapitalMaintainsBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—
10 Dec 2024D. Boral CapitalMaintainsBuy—
25 Nov 2024D. Boral CapitalMaintainsBuy—
11 Nov 2024HC Wainwright & Co.MaintainsBuy—
7 Nov 2024EF HuttonMaintainsBuy—
31 Oct 2024EF HuttonMaintainsBuy—
23 Sept 2024EF HuttonInitiatesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
5 Aug 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMNN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Imunon, Inc. returned −74.5% against +17.0% for the S&P 500, dividends included.

IMNN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26IMNNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMNN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Imunon, Inc. (IMNN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
3.5×

Cheaper than 28% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−429.7%

Higher than 4% of US stocks

Return on assets
−78.0%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Imunon, Inc. (IMNN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Imunon, Inc. has a market value of $8.2M and an enterprise value of $11.5M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$14.6M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$15.1M, after $21K of capital spending.

  • Shares outstanding: 5.6M.

  • Trailing P/E: −0.2×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Imunon, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

IMNN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMNNImunon, Inc.$8.2M
23
CNSPCNS Pharmaceuticals, Inc.$8.3M
22
ALZNAlzamend Neuro, Inc.$8.4M
33
TRAWTraws Pharma, Inc.$7.9M
48
SNGXSoligenix, Inc.$7.9M
25
EVGNEvogene Ltd.$7.8M
24
XCURExicure, Inc.$8.7M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Imunon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMNN news & analysis

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

GlobeNewsWire · 10 Sept 2026positive

IMUNON entered into a Cooperative Research and Development Agreement with the National Cancer Institute to advance the clinical development of IMNN-001. The collaboration with NCI's Cancer Therapy Evaluation Program will evaluate IMNN-001 in new indications and combination regimens.

Why it matters — An IMNN watcher would care because collaboration with the National Cancer Institute could expand the potential clinical applications and development pathways for IMNN-001.

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

GlobeNewsWire · 9 Sept 2026positive

IMUNON announced the full agenda and speaker lineup for its 2026 R&D Day, scheduled for Wednesday, September 23, 2026, at 10:00 a.m. ET in New York City and via live webcast. The event will highlight clinical progress of IMNN-001.

Why it matters — IMNN watchers would care because the R&D Day will provide details on the clinical progress of the company's lead candidate, IMNN-001.

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

GlobeNewsWire · 26 Aug 2026positive

IMUNON announced it will host a 2026 R&D Day featuring oncology experts and company management to discuss its Phase 3 OVATION 3 trial, the supporting science and data, clinical progress, and upcoming milestones for IMNN-001.

Why it matters — The R&D Day will give IMNN watchers a detailed look at the clinical progress and upcoming milestones for IMNN-001's Phase 3 OVATION 3 study.

Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Imunon, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.

Why it matters — A transcript of the Q2 2026 earnings call provides IMNN watchers with direct access to management's commentary on the company's financial performance.

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

GlobeNewsWire · 30 July 2026positive

IMUNON reported stronger-than-expected enrollment in its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer, citing promising survival data and a well-tolerated safety profile from its earlier Phase 2 study. Enrollment is ahead of plan across all study sites, with additional sites opening on schedule.

Why it matters — Ahead-of-plan enrollment and principal investigator confidence in the trial design signal positive momentum for IMNN-001, a key pipeline asset for the company.

FAQ

Frequently asked questions about IMNN stock

What is the IMNN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Imunon, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMNN stock a buy right now?

Of the 4 analysts covering Imunon, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Imunon, Inc. 23 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMNN?

As at 14 Sept 2026, Imunon, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will IMNN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +787.4% from the last close, and Ticker Nerd's factor model ranks Imunon, Inc. 23 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMNN stock forecast for 2030?

No analyst covering Imunon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.

How has IMNN stock performed over the past year?

Imunon, Inc. returned -74.5% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Imunon, Inc. do?

Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases.

What is the latest news on IMNN?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001". IMUNON entered into a Cooperative Research and Development Agreement with the National Cancer Institute to advance the clinical development of IMNN-001. The collaboration with NCI's Cancer Therapy Evaluation Program will evaluate IMNN-001 in new indications and combination regimens.

Company

About Imunon, Inc.

Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases. Its lead program, IMNN-001, is being developed as a localized immunotherapy for advanced ovarian cancer, while its PlaCCine platform supports nucleic acid vaccine research for infectious disease targets. Imunon also advances additional preclinical and early-stage programs across solid tumors and viral indications. Headquartered in Lawrenceville, New Jersey, Imunon plays a specialized role in the biotechnology market by pursuing platform-based treatments that combine immunology, gene delivery, and cancer therapy research.

CEO Dr. Stacy R. Lindborg Ph.D. · 20 employees · United States · https://imunon.com